Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line A375

Medical Oncology

Volumn 23, Issue 3, 2006, Pages 393-402

  Li, Yan ^a   Meng, Yang ^a   Li, Hongyan ^a   Li, Jing ^a   Fu, Jianjiang ^a   Liu, Yue ^a   Chen, Xiaoguang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Apoptosis; Differentiation; Necrosis; PPAR ; ROZ

Indexed keywords

MESSENGER RNA; MONOPHENOL MONOOXYGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BCL 2; PROTEIN P53; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FLUORESCENCE ACTIVATED CELL SORTING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; MALE; MELANOGENESIS; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HUMANS; MODELS, BIOLOGICAL; NECROSIS; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-BCL-2; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 33749374780     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:3:393     Document Type: Article

References (32)

1. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004; 150: 179-185.
2. Gonzalez F, Peters JM, Cattley RC. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activated receptor γ. J Natl Cancer Inst 1990; 90: 1702-1709.
3. Chawla A, Lazar MA. Peroxisome proliferator and retinoid signaling pathways co-regulate preadipocyte phenotype and survival. Proc Natl Acad Sci USA 1994; 91: 1786-1790.
4. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994; 79: 1147-1156.
5. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994; 8: 1224-1234.
6. Yin Y, Russell RG, Dettin LE, et al. Peroxisome Proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res 2005; 65: 1350-1357.
7. Matthew R, Smith L, Kantoff PW. Peroxisome proliferator-activated receptor gamma (PPARγ) as a novel target for prostate cancer. Investigational New Drugs 2002; 20: 195-200.
8. Kato M, Kusumi T, Tsuchida S, Tanaka M, Sasaki M, Kudo H. Induction of differentiation and peroxisome proliferator-activated receptor expression in colon cancer cell lines by troglitazone. J Cancer Res Clin Oncol 2003; 21: 73-79.
9. Bren-Mattison Y, Van Putten V, Chan D, et al. Peroxisome proliferator-activated receptor-c (PPARc) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene 2005; 24: 1412-1422.
10. Seargent JM, Yates EA, Gill JH. GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation. Br J Pharmacol 2004; 143: 993-997.
11. Ying Zhang Y, Wu L-J, Tashiro S-i, Onodera S, and Ikejima T. Intracellular regulation of evodiamine-induced A375-S2 cell death. Biol Pharm Bull 2003; 26(11): 1543-1547.
12. Prasad KN, Edwards-Prasad J. Effect of tocopherol (vitamin E) acid succinate on morphological alterations and growth inhibition in melanoma cells in culture. Cancer Res 1982; 42: 550-555.
13. Winder AJ, Harris H. New assays for the tyrosine hydroxylase and dopa oxidase activities of tyrosinase. Eur J Biochem 1991; 198: 317-326.
14. Hosokawa M, Kudo M, Maeda H, Kohno H, Tanaka T, Miyashita K. Fucoxanthin induces apoptosis and enhances the antiproliferative effect of the PPARγ ligand, troglitazone, on colon cancer cells. Biochim Biophys Acta 2004; 1675: 113-119.
15. Jiang WG, Redfern A, Bryce RP, Mansel RE. Peroxisome proliferators activated receptor-γ (PPAR-γ) mediates the action of gamma linolenic acid in breast cancer cells. Prostaglandins Leukot Essent Fatty Acids 2000; 62(2): 119-127.
16. Nixona JB, Kima K-S, Lambb PW, Bottone Jr. FG, Eling TE. 15-Lipoxygenase-1 has anti-tumorigenic effects in colorectal cancer. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 7-15.
17. Ciciarello M, Mangiacasale R, Casenghi M, et al. p53 displacement from centrosomes and p53-mediated G1 arrest following transient inhibition of the mitotic spindle. J Biol Chem 2001; 276: 19205-19213.
18. Bunz F, Dutriaux A, Lengauer C, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497-1501.
19. Punn A, Mockridge JW, Farooqui S, Marber MS, Heads RJ. Sustained activation of p42/p44 mitogen-activated protein kinase during recovery from simulated ischaemia mediates adaptive cytoprotection in cardiomyocytes. Biochem J 2000; 350: 330-335.
20. Sugino T, Nozaki K, Takagi Y, et al. Activation of mitogen-activated protein kinases after transient forebrain ischemia in gerbil hippocampus. J Neurosci 2000; 20: 4506-4514.
21. Neitzel LT, Neitzel CD, Magee KL, Malafe MP. Angiogenesis correlates with metastasis in melanoma. Ann Surg Oncol 1999; 6: 70-74.
22. Slominski A, Wortsman J, Carlson AJ, Matsuoka LY, Balch CM, Mihm MC. Malignant melanoma. An update. Arch Pathol Lab Med 2001; 125: 1295-1306.
23. Kirsch DG, Doseff A, Chau BN, et al. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol Chem 1999; 274: 21155-21161.
24. Han ZY, Pantazis P, Wyche JH, Kouttab N, Kidd V. A Fas-associated death domain protein-dependent mechanism mediates the apoptotic action of non-steroidal anti-inflammatory drugs in the human leukemic Jurkat cell line. J Biol Chem 2001; 276: 38748-38754.
25. Zhang Y,Wu L-J, Shin-ichi Tashiro S-i, Onodera S, Ikejima T. Intracellular regulation of evodiamine-induced A375-S2 cell death. Biol Pharm Bull 2003; 26(11): 1543-1547.
26. Bates S, Vousden KH. p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev 1996; 6: 12-18.
27. Tsutsui T, Hesabi B, Moons DS, et al. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27Kip1 activity. Mol Cell Biol 1999; 19: 7011-7019.
28. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995; 55: 5187-5190.
29. Ahmed MM, Venkatasubbarao K, Fruitwala SM, et al. EGR-1 induction is required for maximal radiosensitivity in A375-C6 melanoma cells. J Biol Chem 1996; 271: 29231-29237.
30. Li S, Chien S, Branemark PI, Orthop J. Heat shock-induced necrosis and apoptosis in osteoblasts. J Orthop Res 1999; 17(6): 891-899.
31. Ma XL, Kumar S, Gao F, et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 1999; 99(13): 1685-1691.
32. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferatoractivated receptor agonists. The Lancet Oncology 2004; 5: 419-429.